Dysglycaemias and Fluoroquinolones

Drug Safety

Volumn 31, Issue 4, 2008, Pages 283-292

  Lewis, Roshan J ^a   Mohr III, John F ^a,b  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b CUBIST PHARMACEUTICALS INC   (United States)

Author keywords

Fluoroquinolones, adverse reactions; Fluoroquinolones, pharmacodynamics; Hyperglycaemia, drug induced; Hypoglycaemia, drug induced

Indexed keywords

ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; ADRENALIN; ALBUMIN; ANTIDIABETIC AGENT; ATORVASTATIN; C PEPTIDE; CALCIUM ION; CEFTRIAXONE; CIPROFLOXACIN; DIPHENHYDRAMINE; ENOXACIN; GATIFLOXACIN; GLUCOSE; GREPAFLOXACIN; HISTAMINE; INSULIN; INSULIN ANTIBODY; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; NALIDIXIC ACID; PIPERACILLIN PLUS TAZOBACTAM; PRAVASTATIN; QUININE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN; SULFONYLUREA DERIVATIVE; TEMAFLOXACIN; TROVAFLOXACIN; UNINDEXED DRUG;

ANTIBIOTIC THERAPY; DRUG DOSE REDUCTION; DRUG SAFETY; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HEART ARRHYTHMIA; HEMOLYTIC ANEMIA; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN RELEASE; LIVER TOXICITY; NONHUMAN; PRIORITY JOURNAL; QT PROLONGATION; REVIEW; RISK FACTOR;

ANIMALS; ANTI-BACTERIAL AGENTS; FLUOROQUINOLONES; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; RISK FACTORS;

EID: 41149144595     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200831040-00002     Document Type: Review

References (55)

1. Lesher GY, Froelich EJ, Gruett MD, et al. 1,8-Naphthyridine derivatives: a new class of chemotherapeutic agents. J Med Pharm Chem 1962 Sep; 91: 1063-5
2. Zhanel GG, Ennis K, Vercaigne L, et al. A critical review of the fluoroquinolones: focus on respiratory infections. Drugs 2002; 62 (1): 13-59
3. Perry CM, Ormrod D, Hurst M, et al. Gatifloxacin: a review of its use in the management of bacterial infections. Drugs 2002; 62 (1): 169-207
4. Menzies DJ, Dorsainvil PA, Cunha BA, et al. Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents. Am J Med 2002 Aug 15; 113 (3): 232-4
5. Baker SE, Hangii MC. Possible gatifloxacin-induced hypoglycemia. Ann Pharmacother 2002 Nov; 36 (11): 1722-6
6. Biggs WS. Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients. J Am Board Fam Pract 2003 Sep-Oct; 16 (5): 455-7
7. Khovidhunkit W, Sunthornyothin S. Hypoglycemia, hyperglycemia, and gatifloxacin. Ann Intern Med 2004 Dec 21; 141 (12): 969
8. Frothingham R. Glucose homeostasis abnormalities associated with use of gatifloxacin. Clin Infect Dis 2005 Nov 1; 41 (9): 1269-76
9. Blommel AL, Lutes RA. Severe hyperglycemia during renally adjusted gatifloxacin therapy. Ann Pharmacother 2005 Jul-Aug; 39 (7-8): 1349-52
10. Arce FC, Bhasin RS, Pasmantier R. Severe hyperglycemia during gatifloxacin therapy in patients without diabetes. Endocr Pract 2004 Jan-Feb; 10 (1): 40-4
11. Yip C, Lee AJ. Gatifloxacin-induced hyperglycemia: a case report and summary of the current literature. Clin Ther 2006 Nov; 28 (11): 1857-66
12. Goyal V. Hypoglycaemic complication of the quinine. J Assoc Physicians India 2000 May; 48 (5): 548-9
13. Davis TM, Pukrittayakamee S, Supanaranond W, et al. Glucose metabolism in quinine-treated patients with uncomplicated falciparum malaria. Clin Endocrinol (Oxf) 1990 Dec; 33 (6): 739-49
14. Arya TV, Prasad RN, Bhandari S, et al. Spontaneous and quinine induced hypoglycaemia in severe falciparum malaria. Trop Geogr Med 1989 Jan; 41 (1): 73-5
15. White NJ, Warrell DA, Chanthavanich P, et al. Severe hypoglycemia and hyperinsulinemia in falciparum malaria. N Engl J Med 1983 Jul 14; 309 (2): 61-6
16. Bokvist K, Rorsman P, Smith PA. Effects of external tetraethylammonium ions and quinine on delayed rectifying K+ channels in mouse pancreatic beta-cells. J Physiol 1990 Apr; 423: 311-25
17. Bokvist K, Rorsman P, Smith PA. Block of ATP-regulated and Ca2(+)-activated K+ channels in mouse pancreatic beta-cells by external tetraethylammonium and quinine. J Physiol 1990 Apr; 423: 327-42
18. Petit P, Loubatieres-Mariani MM. Potassium channels of the insulin-secreting B cell. Fundam Clin Pharmacol 1992; 6 (3): 123-34
19. Ashcroft FM. ATP-sensitive potassium channelopathies: focus on insulin secretion. J Clin Invest 2005 Aug; 115 (8): 2047-58
20. MacDonald PE, Wheeler MB. Voltage-dependent K(+) channels in pancreatic beta cells: role, regulation and potential as therapeutic targets. Diabetologia 2003 Aug; 46 (8): 1046-62
21. Maeda N, Tamagawa T, Niki I, et al. Increase in insulin release from rat pancreatic islets by quinolone antibiotics. Br J Pharmacol 1996 Jan; 117 (2): 372-6
22. Cryer PE, Fisher JN, Shamoon H. Hypoglycemia. Diabetes Care 1994 Jul; 17 (7): 734-55
23. Kagansky N, Levy S, Rimon E, et al. Hypoglycemia as a predictor of mortality in hospitalized elderly patients. Arch Intern Med 2003 Aug 11-25; 163 (15): 1825-9
24. Gaglia JL, Wyckoff J, Abrahamson MJ. Acute hyperglycemic crisis in the elderly. Med Clin North Am 2004 Jul; 88 (4): 1063-84, xii
25. Lopes EP, Oliveira PM, Silva AE, et al. Exacerbation of type 2 diabetes mellitus during interferon-alfa therapy for chronic hepatitis B. Lancet 1994 Jan 22; 343 (8891): 244
26. Cozzolongo R, Betterle C, Fabris P, et al. Onset of type 1 diabetes mellitus during peginterferon alpha-2b plus ribavirin treatment for chronic hepatitis C. Eur J Gastroenterol Hepatol 2006 Jun; 18 (6): 689-92
27. Garbitelli VP. Tetracycline reduces the need for insulin. N Y State J Med 1987 Oct; 87 (10): 576
28. Basaria S, Braga M, Moore WT. Doxycycline-induced hypoglycemia in a nondiabetic young man. South Med J 2002 Nov; 95 (11): 1353-4
29. Strevel EL, Kuper A, Gold WL. Severe and protracted hypoglycaemia associated with co-trimoxazole use. Lancet Infect Dis 2006 Mar; 6 (3): 178-82
30. Gribble FM, Davis TM, Higham CE, et al. The antimalarial agent mefloquine inhibits ATP-sensitive K-channels. Br J Pharmacol 2000 Oct; 131 (4): 756-60
31. Bussing R, Gende A. Severe hypoglycemia from clarithromycin-sulfonylurea drug interaction. Diabetes Care 2002 Sep; 25 (9): 1659-61
32. Zunkler BJ, Wos M. Effects of lomefloxacin and norfloxacin on pancreatic beta-cell ATP-sensitive K(+) channels. Life Sci 2003 Jun 13; 73 (4): 429-35
33. Zunkler BJ, Claassen S, Wos-Maganga M, et al. Effects of fluoroquinolones on HERG channels and on pancreatic beta-cell ATP-sensitive K+ channels. Toxicology 2006 Dec 7; 228 (2-3): 239-48
34. Saraya A, Yokokura M, Gonoi T, et al. Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K+ channels. Eur J Pharmacol 2004 Aug 16; 497 (1): 111-7
35. Yamada C, Nagashima K, Takahashi A, et al. Gatifloxacin acutely stimulates insulin secretion and chronically suppresses insulin biosynthesis. Eur J Pharmacol 2006 Dec 28; 553 (1-3): 67-72
36. Ishiwata Y, Sanada Y, Yasuhara M. Effects of gatifloxacin on serum glucose concentration in normal and diabetic rats. Biol Pharm Bull 2006 Mar; 29 (3): 527-31
37. Ishiwata Y, Itoga Y, Yasuhara M. Effect of levofloxacin on serum glucose concentration in rats. Eur J Pharmacol 2006 Dec 3; 551 (1-3): 168-74
38. Hori S, Kizu J, Kawamura M. Effect of fluoroquinolones on plasma glucose levels in fasted and glucose-loaded mice. J Infect Chemother 2006 Apr; 12 (2): 109-11
39. Coblio NA, Mowrey K, McCright P, et al. Use of a data warehouse to examine the effect of fluoroquinolones on glucose metabolism. Am J Health Syst Pharm 2004 Dec 1; 61 (23): 2545-8
40. Gajjar DA, LaCreta FP, Kollia GD, et al. Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise. Pharmacotherapy 2000 Jun; 20 (6 Pt 2): 76S-86S
41. Park-Wyllie LY, Juurlink DN, Kopp A, et al. Outpatient gatifloxacin therapy and dysglycemia in older adults. N Engl J Med 2006 Mar 30; 354 (13): 1352-61
42. Cannon CP, Braunwald E, McCabe CH, et al. Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome. N Engl J Med 2005 Apr 21; 352 (16): 1646-54
43. Lomaestro BM, Lodise TP. Comparison of glucose intolerance between gatifloxacin and piperacillin-tazobactam in elderly hospitalized patients [abstract]. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2004 Oct 30-Nov 2; Washington, DC: 1093
44. Graumlich JF, Habis S, Avelino RR, et al. Hypoglycaemia in inpatients after gatifloxacin or levofloxacin therapy: nested case-control study. Pharmacotherapy 2005 Oct; 25 (10): 1296-302
45. Owens Jr RC, Ambrose PG. Torsades de pointes associated with fluoroquinolones. Pharmacotherapy 2002 May; 22 (5): 663-8; discussion 8-72
46. Lodise T, Graves J, Miller C, et al. Effects of gatifloxacin and levofloxacin on rates of hypoglycemia and hyperglicemia among elderly hospitalized patients. Pharmacotherapy 2007 Nov; 27 (11): 1498-505
47. Mohr JF, McKinnon PS, Peymann PJ, et al. A retrospective, comparative evaluation of dysglycemias in hospitalized patients receiving gatifloxacin, levofloxacin, ciprofloxacin, or ceftriaxone. Pharmacotherapy 2005 Oct; 25 (10): 1303-9
48. Ambrose PG, Bhavnani SM, Cirincione BB, et al. Gatifloxacin and the elderly: pharmacokinetic-pharmacodynamic rationale for a potential age-related dose reduction. J Antimicrob Chemother 2003 Sep; 52 (3): 435-40
49. Mohr J, Peymann P, Troxell E, et al. Risk factors for insulin cemia in hospitalized adults receiving gatifloxacin: a retrospective, nested case controlled analysis. Clin Ther 2008; 30: 152-7
50. Friedrich LV, Dougherty R. Fatal hypoglycemia associated with levofloxacin. Pharmacotherapy 2004 Dec; 24 (12): 1807-12
51. Lawrence KR, Adra M, Keir C. Hypoglycemia-induced anoxic brain injury possibly associated with levofloxacin. J Infect 2006 Jun; 52 (6): e177-80
52. Wang S, Rizvi AA. Levofloxacin-induced hypoglycemia in a nondiabetic patient. Am J Med Sci 2006 Jun; 331 (6): 334-5
53. Roberge RJ, Kaplan R, Frank R, et al. Glyburide-ciprofloxacin interaction with resistant hypoglycemia. Ann Emerg Med 2000 Aug; 36 (2): 160-3
54. Lin G, Hays DP, Spillane L. Refractory hypoglycemia from ciprofloxacin and glyburide interaction. J Toxicol Clin Toxicol 2004; 42 (3): 295-7
55. Gavin 3rd JR, Kubin R, et al. Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies. Drug Saf 2004; 27 (9): 671-86